The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

This approval marks the eighth disease indication for Dupixent as a new alternative for patients—many of whom are elderly and ...

The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid  Approval based on pivotal results showing improvements in sustained disease remission and ...

Sanofi and Regeneron are committed to helping patients in the US who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay® program. For ...

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use co ...

Medical news, education and information for physicians and health care professionals, presented by specialty and topic. From Healio and the Wyanoke Group.

Sanofi & Regeneron’s Dupixent receives US FDA approval to treat patients with bullous pemphigoid: Paris Saturday, June 21, 2025, 12:00 Hrs [IST] The US Food and Drug Administrat ...

Apr. 3, 2025 — Certain antibiotic-resistant infections could be treated with precision medicine in the future, thanks to a new resource mapping plasmids the ultimate vehicle of rapid bacterial ...

The elusive and enigmatic origin of AIDS-associated Kaposi's sarcoma (AIDS-KS) makes it a complex tumor and therefore difficult to treat. Here we demonstrate that AIDS-KS cells express surface ...